Ripple Therapeutics
June 16, 2025
Company Presentation
Platform for Therapeutics
Ripple Therapeutics is clinical stage biotech company with a focus on treating ophthalmic diseases. The company's core technology is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without an added delivery system. These prodrugs are highly customized to tailor both the drug dose and duration, resulting in an improved safety profile, extended therapeutic benefit and reduced treatment burden for both the patient and their physician. While we are focused on ophthalmology the platform has broad applications for indications where sustained drug delivery is needed.
Company HQ City:
Toronto
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2020
Lead Product in Development:
RTC-620, intracameral bimatoprost sustained release implant, in licensing agreement with AbbVie; intravitreal statin implant for intermediate dry AMD
CEO
Tom Reeves
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4 products with preclinical data and platform for therapeutic area expansion
When you expect your next catalyst update?
Preclinical POC of statin implant
What is your next catalyst (value inflection) update?
Q3/25
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}